U.S. Pharmaceutical Cold Chain Faces Pressure to Modernize

The United States pharmaceutical cold chain is playing catch-up with the industry’s growth rate as the rise of mRNA platforms, CAR-T cell therapies and precision biologics collides with stagnant temporary cold-storage capacity. Firms are often forced to rely on over-the-road trailers and other temporary units rather than planned, high-performance temporary structures, increasing the risk of temperature excursions that cost the industry billions of dollars every year.

The specialized network of refrigerators, freezers and climate-controlled logistics required to keep temperature-sensitive drugs within strict limits has stagnated under a traditional growth plan. While the U.S. is the world’s largest market for pharmaceuticals, its temporary storage solutions typically lag behind Europe and Asia in cold-chain sophistication.

Many domestic solutions are essentially repurposed shipping containers or basic refrigerated boxes that lack the redundancy, precision and IoT integration found in modern specialized systems. These solutions often have less insulation or rely on one temperature-control system that, if it fails, has no backup.

A primary hurdle facing U.S. infrastructure is not lack of capital, but that companies tend to stick to traditional cold storage methods that have worked for decades. Pharmaceutical companies also need to consider having capacity on-site to efficiently manage inventory until a two- to three-year construction project is completed.

Warehousing and distribution infrastructure are frequently the very last considerations when a biotechnology firm receives funding, with primary priorities almost always laboratory equipment, talent acquisition and administrative office space. Companies often wait until a product is ready for phase 3 trials or full commercial launch before realizing the existing footprint lacks the specialized capacity to store the product.

By the time this realization occurs, the window for implementing a planned, superior solution has closed. This urgency leads to the procurement of whatever is immediately available, such as over-the-road trailers and other temporary units, rather than a planned, high-performance temporary structure that can be used until the construction of the permanent structure is complete.

Annual losses near $35 billion are attributed to cold-chain failures. Biologics are incredibly fragile and highly sensitive to environmental changes, and even a minor temperature excursion—a fluctuation of a few degrees for a few hours—can cause protein denaturation or aggregation.

The most critical driver of infrastructure enhancement is patient safety. A compromised vaccine may not show visible signs of degradation, but its potency is diminished.